RT Journal Article
SR Electronic
T1 An Open Labelled, Active Controlled, Three-Arm, Parallel-Group study of the safety and efficacy of the oral formulation of Oral Iodine Complex (RENESSANS) administered alone and in combination with standard interferon therapy in patients suffering from Chronic HCV Hepatitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.27.20141473
DO 10.1101/2020.06.27.20141473
A1 Ghiasun Nabi
A1 Muhammad Nasir
A1 Ghias ulhasan
A1 Israr Toor
A1 Fawad Zia
A1 Imran Hassan
A1 Muhammad Faisal Nadeem
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.27.20141473.abstract
AB Iodine has strong antimicrobial properties and has been used in topical applications as antiseptic. Its systemic use in form of iodine complexes derived from dried seaweed extract is beneficial in treating various disorders. Hepatitis C Virus (HCV) chronic infection is present in 6-10% of the Pakistani population and is a major healthcare burden that could benefit from innovative therapeutic regimens.Objective A pilot study has shown the safety and efficacy of iodine complexes in chronic Hepatitis C virus infection. and this clinical study is aimed to further explore the previous findings.Methods This is an open-labeled, active-controlled, three-arm, parallel-group study including 90 patients of chronic HCV infection with each arm having 30 patients. The patient groups received 15mg/day iodine complex only, the standard of care therapy interferon+ribavirin, and iodine complex in combination with interferon+ribavirin regimen for 6 months. Efficacy assessment will base upon post-treatment Rapid Virological Response (RVR) at 4 weeks, Early Virological Response (EVR) at 12 weeks, and End of Treatment Viral Response (ETR) at 24/48 weeks.Results As only 3.33% of patients showed at the ETR with iodine complex alone, combination with interferon+ribavirin showed significant improvement in comparison to interferon+ribavirin alone. Iodine complex+ interferon+ribavirin showed 80% RVR and 90% ETR while the standard of care therapy showed 66.7% RVR and 76.67% ETR, respectively. No additional adverse events of iodine complex were observed.Conclusion Iodine complex showed a significant synergistic effect when combined interferon+ribavirin regimen and could be useful in relapsers and non-responders.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01463592Funding StatementThe study was funded by MTI Medical, Pakistan;Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was IRB approved from Post Graduate Medical Institute, Lahore.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have all data available. Will include more data if required. https://clinicaltrials.gov/ct2/show/NCT01463592